A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer
Status:
WITHDRAWN
Trial end date:
2025-05-23
Target enrollment:
Participant gender:
Summary
Trial to investigate if the addition of two novel immunotherapy agents in combination with a chemotherapy agent can reduce the size of the cancer and how long they can delay the growth of the cancer in patients with metastatic pancreatic cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Karen Carty
Collaborators:
NHS Greater Glasgow and Clyde University of Glasgow